Adma Biologics, Inc. (ADMA)
ADMA Biologics makes immune globulin treatments from human blood plasma for patients with weakened immune systems. It last closed at $11.06 on Nov 2, down 3.15% on the day. ADMA reports earnings on Wed, Nov 4, 2026. In the past 30 days there were 1 dark pool print totaling $1.6M, the largest $1.6M.
Key Stats
Last 12 monthsNot reported for this period.
From ADMA's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 5). Last 12 months adds up the four latest quarters.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jul 15 | Mizuho | Maintained | Buy | $17 |
| Apr 21 | Canaccord Genuity | Initiated | Buy | $21 |
Technical Analysis
The stock is 2% above its 20 day and 9% above its 50 day average. It is 1% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the 200 day average at $10.93, and the nearest resistance the Pivot at $11.23.
| RSI (14) | 57.00 | Middle of its range | Neutral |
| MACD | 0.39 | Above its signal line | Bullish |
| Stochastic | 74.0 | Middle of its range | Neutral |
| ADX (14) | 28.6 | Trending up | |
| Williams %R | -50.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 75.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −0.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.40 | Typical daily range, 3.6% of price |
| RSI (14) | 56.02 | Middle of its range | Neutral |
| MACD | -0.08 | Above its signal line | Bullish |
| Stochastic | 80.2 | Near the top of its range | Overbought |
| ADX (14) | 24.3 | Weak trend | |
| Williams %R | -25.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 168.8 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +18.4% | Change over 10 sessions | Bullish |
| ATR (14) | $0.95 | Typical daily range, 8.6% of price |
What happened before
See how ADMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ADMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in ADMA in the last 90 days.
Dark Pool
30DADMA Institutional Ownership
Hedge fund holdings →| # | Fund | Shares | Of company | Value | Change | |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 38.4M | 17.12% | $321.0M | +1.5M | Added |
| 2 | State Street Corp | 17.1M | 7.64% | $143.3M | +3M | Added |
| 3 | Vanguard Capital Management LLC | 10.1M | 4.51% | $84.6M | −203K | Trimmed |
| 4 | Vanguard Portfolio Management LLC | 10.1M | 4.50% | $84.4M | +1.2M | Added |
| 5 | Rubric Capital Management LP | 9.3M | 4.17% | $78.2M | +7.5M | Added |
| 6 | Capital Research Global Investors | 8.8M | 3.91% | $73.3M | −2.4M | Trimmed |
| 7 | First Trust Advisors LP | 7.8M | 3.48% | $65.3M | +7.4M | Added |
| 8 | Geode Capital Management, LLC | 6.1M | 2.71% | $50.7M | +236K | Added |
| 9 | Caligan Partners LP | 5.7M | 2.56% | $47.9M | +968K | Added |
| 10 | D. E. Shaw & Co., Inc. | 5.3M | 2.35% | $44.1M | +4.7M | Added |
| 11 | Nantahala Capital Management, LLC | 4.7M | 2.11% | $39.5M | +4.7M | New |
| 12 | Dimensional Fund Advisors LP | 3.6M | 1.61% | $30.2M | −1.4M | Trimmed |
| 13 | Goldman Sachs Group Inc | 3.5M | 1.57% | $29.4M | +710K | Added |
| 14 | B Group, Inc. | 3.3M | 1.46% | $27.3M | +55K | Added |
| 15 | Nuveen, LLC | 3.3M | 1.46% | $27.3M | −2.8M | Trimmed |
| 16 | Duquesne Family Office LLC | 2.8M | 1.24% | $23K | +1.2M | Added |
| 17 | Northern Trust Corp | 2.4M | 1.08% | $20.2M | +139K | Added |
| 18 | Morgan Stanley | 2.3M | 1.01% | $19.0M | −169K | Trimmed |
| 19 | Ranger Investment Management, L.P. | 2.1M | 0.94% | $17.7M | −168K | Trimmed |
| 20 | Charles Schwab Investment Management Inc | 2.1M | 0.93% | $17.5M | −3,178 | Trimmed |
| 21 | Two Sigma Investments, LP | 2M | 0.90% | $16.9M | −72K | Trimmed |
| 22 | Kennedy Capital Management LLC | 1.8M | 0.78% | $14.7M | +1.3M | Added |
| 23 | Vanguard Fiduciary Trust Co | 1.7M | 0.74% | $13.8M | +17K | Added |
| 24 | Fundsmith LLP | 1.6M | 0.74% | $13.8M | 0 | No change |
| 25 | Bank of America Corp /de/ | 1.6M | 0.74% | $13.8M | −2.4M | Trimmed |
- Rubric Capital Management LP+7.5M sh$63.0M
- First Trust Advisors LP+7.4M sh$62.3M
- Nantahala Capital Management, LLC+4.7M sh$39.5M
- D. E. Shaw & Co., Inc.+4.7M sh$39.5M
- State Street Corp+3M sh$25.4M
- BlackRock, Inc.+1.5M sh$12.8M
- American Century Companies Inc−4.6M sh−$38.2M
- Citadel Advisors LLC−4.4M sh−$37.2M
- Invesco Ltd.−3.6M sh−$29.9M
- Point72 Asset Management, L.P.−2.9M sh−$24.1M
- Nuveen, LLC−2.8M sh−$23.8M
- Capital Research Global Investors−2.4M sh−$20.4M
- Principal Financial Group IncAdded+498K shNov 2
- Y-Intercept (Hong Kong) LtdTrimmed−422K shOct 16
- Bridge City Capital, LLCNew+266K shOct 29
- Marathon Capital ManagementTrimmed−171K shOct 23
- Strs OhioAdded+68K shOct 30
- Yorktown Management & Research Co IncNew+44K shOct 28
- Profund Advisors LLCTrimmed−41K shOct 29
- City Center Advisors, LLCNew+38K shOct 8
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. "Held by funds" adds up the shares every 13F filer reported, over shares outstanding. Filings come up to 45 days after the quarter ends. Put/call compares the value of puts and calls funds reported ($8.7M in puts, $17.9M in calls), leaving out market makers and bank trading desks. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADMA is in one of them and how their past ADMA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ADMA in an article yet. Here's the latest on the wider market.
ADMA Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $15K – $50K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Mar 4, 2026 | May 14, 2026 | 71 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Feb 26, 2026 | May 14, 2026 | 77 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Adma Biologics
ADMA Biologics is a biopharmaceutical company based in Ramsey, New Jersey. It makes specialty biologics from human blood plasma for people with weakened immune systems and for people at risk of certain infectious diseases. Its main products are ASCENIV and BIVIGAM, two immune globulin treatments for primary immunodeficiency, and Nabi-HB, which is used after exposure to hepatitis B. The company also operates plasma collection centers, sells some plasma to other manufacturers, and its products are mainly used by physician specialists.
- Headquarters
- Ramsey, NJ
- Website
- admabiologics.com ↗